Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Main diagnosis: aplastic anemia~* Absence of severe and/or uncontrolled comorbidities~* Confirmed iron overload (serum ferritin ≥ 1000 mkg/L)~* Serum creatinine is not higher than the upper limit of normal for the given age~* Absence of severe proteinuria. Protein/Creatinine ratio should be \< 0.5 mg/mg~* Liver enzymes are \< 5 ULN~* Completion of a scheduled cycle of immunosuppressive treatment program, with no severe infectious or generalized hemorrhagic complications~* WHO (ECOG) performance status ≤ 2~Exclusion Criteria:~* No signed informed consent form~* Patient is under 18 years old~* Severe concomitant condition~* Severe infectious and generalized haemorrhagic complication following regular planned cycle of programmed immune suppressive treatment.~* History of increased sensitivity to active substance and any other ingredient of the medicinal product.~* Creatinine clearance (CC) \< 60 ml/min and/or creatinine concentration in blood serum is 2 or more times higher than upper limit of age normal by results of 2 tests at Visits 1 and 2.~* Severe liver disorders (class C by Child-Pugh scale).~* Patients with aplastic anaemia in which chelator treatment will be ineffective due to rapid progression of the disease.~* Significant proteinuria basing on protein creatinine ratio \> 1.0 mg/ml in urine sample from second urination at Visits 1 and 2 (or as an alternative in 2 of 3 urine samples at screening);~* Rare hereditary disorders related to galactose intolerance, severe deficit of lactase or glucose-galactose malabsorption;~* Pregnancy, lactation;~* Level of liver enzymes higher than 5 upper limits of age normal at Visits 1 and 2.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Serum ferritin level ≥ 1,000 μg/l (Type: EXPERIMENTAL): Transfusion-dependent adult patients with AA and serum ferritin ≥ 1000 mg/L on programmed immune suppressive treatment with cyclosporine A who were receiving chelation with Exjade (deferasirox) during the study
- Serum ferritin level < 1,000 μg/l (Type: EXPERIMENTAL): Transfusion-dependent adult patients with AA and serum ferritin \< 1,000 mg/L on programmed immune suppressive treatment with cyclosporine A who were not receiving the investigational product

Based on this trial design, predict the completion outcome and termination type (if applicable).